Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Transplant Cell Ther. 2020 Dec 11;27(2):163.e1–163.e7. doi: 10.1016/j.jtct.2020.10.016

Table 2.

Transplant outcome according to no auto or prior auto HCT

Total (n=150) No Auto (n=100) Prior Auto (n=50)
Grade II-IV acute GVHD at day 100, % 27 25 30
Grade III-IV acute GVHD at day 100, % 4 2 8
Chronic extensive GVHD (5 years), % 48 44 56
NRM (1/5 years), % 9/13 12/16 4/6
Relapse/Progression (1/5 years), % 35/50 31/43 42/64
Overall Survival (1/5 years), % 73/53 73/55 74/48
PFS (1/5 years), % 56/37 57/41 54/30

Data are survival or cumulative incidence percentage. Study was not designed to compare outcomes between no auto and prior auto groups.

Abbreviations: GVHD, graft-versus-host-disease; NRM, non-relapse mortality; PFS, progression-free survival